Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?

被引：9

作者：

Connolly, D. ^{[1
,2
]}

Black, A. ^{[2
]}

Murray, L. J. ^{[2
]}

Nambirajan, T. ^{[1
]}

Keane, P. F. ^{[1
]}

Gavin, A. ^{[3
]}

机构：

[1] Belfast City Hosp, Dept Urol, Belfast BT9 7AB, Antrim, North Ireland

[2] Queens Univ Belfast, Canc Epidemiol & Prevent Res Grp, Belfast, Antrim, North Ireland

[3] Queens Univ Belfast, No Ireland Canc Registry, Belfast, Antrim, North Ireland

来源：

PROSTATE CANCER AND PROSTATIC DISEASES | 2009年 / 12卷 / 01期

关键词：

decrease; pattern; PSA; variability; BIOLOGICAL VARIATION; CANCER DETECTION; MEN; VOLUNTEERS;

D O I：

10.1038/pcan.2008.37

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To examine the practice of repeating an abnormal prostate-specific antigen (PSA) level before proceeding to prostate biopsy, we assessed the pattern of PSA change following an initially raised (>= 4.0 ng ml(-1)) PSA, and the relationship of this to prostate cancer diagnosis. In 7052 men, 71.2% with initially raised PSA had a reduction in PSA, with values <4.0 ng ml(-1) in 37.8%. A total of 43.0% of men with prostate cancer showed a PSA decrease below their baseline level. Short-term decreases in PSA may occur in men with prostate cancer, including high-grade cancer, and so should not influence the decision to proceed to prostate biopsy.

引用

页码：47 / 51

页数：5

共 15 条

[11] Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/ml range in male volunteers [J].

Prestigiacomo, AF ;

Stamey, TA .

JOURNAL OF UROLOGY, 1996, 155 (06) :1977-1980

[12] Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy [J].

Singh, R ;

Cahill, D ;

Popert, R ;

O'Brien, TS .

BJU INTERNATIONAL, 2003, 92 (09) :932-935

[13] RATE OF CHANGE IN SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS AS A METHOD FOR PROSTATE-CANCER DETECTION [J].

SMITH, DS ;

CATALONA, WJ .

JOURNAL OF UROLOGY, 1994, 152 (04) :1163-1167

[14] Biological variation of total prostate-specific antigen:: A survey of published estimates and consequences for clinical practice [J].

Sölétormos, G ;

Semjonow, A ;

Sibley, PEC ;

Lamerz, R ;

Petersen, PH ;

Albrecht, W ;

Bialk, P ;

Gion, M ;

Junker, F ;

Schmid, HP ;

Van Poppel, H .

CLINICAL CHEMISTRY, 2005, 51 (08) :1342-1351

[15] Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter [J].

Thompson, IM ;

Pauler, DK ;

Goodman, PJ ;

Tangen, CM ;

Lucia, MS ;

Parnes, HL ;

Minasian, LM ;

Ford, LG ;

Lippman, SM ;

Crawford, ED ;

Crowley, JJ ;

Coltman, CA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (22) :2239-2246

← 1 2 →